Vir Biotechnology, Inc. VIR
Set alert
11.30 USD -0.45 -3.83%
At close · Oct 30
11.46 +0.16 +1.42%
After hours · Oct 30, 6:53 PM ET
11.18 Day range 11.84
5.12 52-week range 11.93
- YTD
- +87.40%
- 1 year
- +90.56%
- Open
- 11.63
- Prev close
- 11.75
- Mkt cap
- 1.91B
- Vol
- 1.27M
- Avg vol
- 1.92M
- EPS
- -1.76
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 11.18
- High
- 11.84
- Forward P/E
- -4.54
- Beta
- 1.59
- Short ratio
- 7.15
- Inst. own
- 84.42%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 10.90
- 200-d avg
- 9.50
- 1y target
- 21.00
MAX chart
Events in this range
- Aug 6, 2025Earnings: -0.8; estimate -0.72; surprise -11.11%
- Nov 5, 2025Earnings: -1.17; estimate -0.7; surprise -67.14%
- Feb 23, 2026Earnings: -0.31; estimate -0.42; surprise 26.19%
- Feb 24, 2026Rating: Morgan Stanley · Overweight → Overweight
- Feb 25, 2026Rating: Barclays · Overweight → Overweight
- Mar 4, 2026Rating: HC Wainwright & Co. · Buy → Buy
- May 6, 2026Earnings: -0.85; estimate -0.01; surprise -8400%
- Jun 3, 2026Rating: Leerink Partners · Outperform → Outperform
- Jun 11, 2026Rating: Morgan Stanley · Overweight → Overweight
- Aug 5, 2026Earnings: 0.47; estimate 0.3326; surprise 41.31%
- Oct 7, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Nov 4, 2026Earnings: —; estimate -0.73934; surprise —%
Signals (135)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 26, 2026 | 5 days ago |
| MACD: Buy Signal | Oct 26, 2026 | 5 days ago |
| MACD: Sell Signal | Oct 19, 2026 | 1 week ago |
| SMA: Bearish | Oct 12, 2026 | 2 weeks ago |
| MACD: Buy Signal | Aug 31, 2026 | 2 months ago |
| SMA: Bullish | Aug 17, 2026 | 2 months ago |
| SMA: Bullish | Aug 10, 2026 | 2 months ago |
| SMA: Bearish | Jul 20, 2026 | 3 months ago |
| SMA: Bearish | Jul 20, 2026 | 3 months ago |
| SMA: Bullish | Jun 22, 2026 | 4 months ago |
| SMA: Bearish | Jun 1, 2026 | 5 months ago |
| SMA: Bullish | May 25, 2026 | 5 months ago |
| MACD: Sell Signal | May 11, 2026 | 5 months ago |
| SMA: Bearish | May 4, 2026 | 6 months ago |
| RSI: Overbought | Apr 13, 2026 | 6 months ago |
| RSI: Overbought | Feb 23, 2026 | 8 months ago |
| SMA: Bullish | Jan 12, 2026 | 9 months ago |
| SMA: Bearish | Dec 29, 2025 | 10 months ago |
| SMA: Bullish | Dec 22, 2025 | 10 months ago |
| SMA: Bearish | Dec 15, 2025 | 10 months ago |
| SMA: Bullish | Nov 10, 2025 | 11 months ago |
| SMA: Bullish | Nov 10, 2025 | 11 months ago |
| SMA: Bearish | Nov 3, 2025 | 12 months ago |
| SMA: Bearish | Nov 3, 2025 | 12 months ago |
| SMA: Bullish | Sep 22, 2025 | 1 year ago |
| SMA: Bullish | Sep 15, 2025 | 1 year ago |
| SMA: Bearish | Sep 8, 2025 | 1 year ago |
| SMA: Bullish | Sep 1, 2025 | 1 year ago |
| SMA: Bearish | Jul 28, 2025 | 1 year ago |
| SMA: Bullish | Jun 30, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 30, 2025 | 1 year ago |
| SMA: Bearish | Jun 9, 2025 | 1 year ago |
| SMA: Bullish | Jun 2, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 3, 2025 | 1 year ago |
| SMA: Bearish | Feb 24, 2025 | 1 year ago |
| SMA: Bearish | Feb 24, 2025 | 1 year ago |
| SMA: Bullish | Jan 6, 2025 | 1 year ago |
| SMA: Bullish | Jan 6, 2025 | 1 year ago |
| SMA: Bearish | Dec 9, 2024 | 1 year ago |
| SMA: Bullish | Dec 2, 2024 | 1 year ago |
| SMA: Bearish | Nov 11, 2024 | 1 year ago |
| SMA: Bearish | Nov 11, 2024 | 1 year ago |
| SMA: Bullish | Oct 28, 2024 | 2 years ago |
| SMA: Bullish | Oct 28, 2024 | 2 years ago |
| MACD: Buy Signal | Oct 28, 2024 | 2 years ago |
| MACD: Sell Signal | Aug 12, 2024 | 2 years ago |
| SMA: Bearish | Jul 29, 2024 | 2 years ago |
| SMA: Bearish | Jul 29, 2024 | 2 years ago |
| SMA: Bullish | Jul 15, 2024 | 2 years ago |
| SMA: Bullish | Jul 15, 2024 | 2 years ago |
| SMA: Bearish | Jun 17, 2024 | 2 years ago |
| SMA: Bearish | Jun 10, 2024 | 2 years ago |
| SMA: Bullish | May 13, 2024 | 2 years ago |
| SMA: Bullish | May 13, 2024 | 2 years ago |
| SMA: Bearish | May 6, 2024 | 2 years ago |
| SMA: Bearish | May 6, 2024 | 2 years ago |
| SMA: Bullish | Apr 29, 2024 | 2 years ago |
| SMA: Bullish | Apr 29, 2024 | 2 years ago |
| SMA: Bearish | Apr 1, 2024 | 2 years ago |
| SMA: Bearish | Mar 18, 2024 | 2 years ago |
| SMA: Bullish | Feb 12, 2024 | 2 years ago |
| SMA: Bullish | Feb 12, 2024 | 2 years ago |
| RSI: Oversold | Jan 29, 2024 | 2 years ago |
| SMA: Bearish | Jan 15, 2024 | 2 years ago |
| SMA: Bullish | Nov 13, 2023 | 2 years ago |
| MACD: Buy Signal | Nov 13, 2023 | 2 years ago |
| RSI: Oversold | Jul 17, 2023 | 3 years ago |
| MACD: Sell Signal | Jul 3, 2023 | 3 years ago |
| SMA: Bearish | Jun 12, 2023 | 3 years ago |
| SMA: Bearish | Jun 5, 2023 | 3 years ago |
| SMA: Bullish | May 22, 2023 | 3 years ago |
| SMA: Bearish | May 1, 2023 | 3 years ago |
| MACD: Buy Signal | Apr 24, 2023 | 3 years ago |
| SMA: Bullish | Apr 17, 2023 | 3 years ago |
| SMA: Bullish | Apr 10, 2023 | 3 years ago |
| SMA: Bearish | Feb 20, 2023 | 3 years ago |
| MACD: Sell Signal | Feb 20, 2023 | 3 years ago |
| SMA: Bearish | Feb 6, 2023 | 3 years ago |
| SMA: Bullish | Jan 9, 2023 | 3 years ago |
| SMA: Bearish | Dec 26, 2022 | 3 years ago |
| SMA: Bullish | Oct 31, 2022 | 4 years ago |
| MACD: Buy Signal | Oct 31, 2022 | 4 years ago |
| SMA: Bullish | Oct 24, 2022 | 4 years ago |
| MACD: Sell Signal | Sep 12, 2022 | 4 years ago |
| SMA: Bearish | Aug 15, 2022 | 4 years ago |
| SMA: Bearish | Aug 15, 2022 | 4 years ago |
| SMA: Bullish | Jul 4, 2022 | 4 years ago |
| SMA: Bullish | Jun 13, 2022 | 4 years ago |
| SMA: Bearish | Jun 6, 2022 | 4 years ago |
| SMA: Bullish | May 16, 2022 | 4 years ago |
| MACD: Buy Signal | May 16, 2022 | 4 years ago |
| MACD: Sell Signal | Jan 17, 2022 | 4 years ago |
| SMA: Bearish | Jan 3, 2022 | 4 years ago |
| SMA: Bearish | Jan 3, 2022 | 4 years ago |
| SMA: Bullish | Dec 27, 2021 | 4 years ago |
| SMA: Bearish | Dec 20, 2021 | 4 years ago |
| MACD: Buy Signal | Dec 6, 2021 | 4 years ago |
| SMA: Bullish | Nov 29, 2021 | 4 years ago |
| SMA: Bullish | Nov 29, 2021 | 4 years ago |
| MACD: Sell Signal | Sep 27, 2021 | 5 years ago |
| SMA: Bearish | Sep 20, 2021 | 5 years ago |
| SMA: Bearish | Sep 20, 2021 | 5 years ago |
| SMA: Bullish | Aug 23, 2021 | 5 years ago |
| MACD: Buy Signal | Aug 23, 2021 | 5 years ago |
| SMA: Bullish | Aug 9, 2021 | 5 years ago |
| SMA: Bearish | Jun 28, 2021 | 5 years ago |
| SMA: Bearish | Jun 21, 2021 | 5 years ago |
| SMA: Bullish | Jun 7, 2021 | 5 years ago |
| SMA: Bullish | May 31, 2021 | 5 years ago |
| SMA: Bearish | May 24, 2021 | 5 years ago |
| SMA: Bullish | May 17, 2021 | 5 years ago |
| SMA: Bearish | May 3, 2021 | 5 years ago |
| MACD: Sell Signal | Mar 29, 2021 | 5 years ago |
| SMA: Bearish | Mar 1, 2021 | 5 years ago |
| RSI: Overbought | Jan 25, 2021 | 5 years ago |
| MACD: Buy Signal | Jan 18, 2021 | 5 years ago |
| SMA: Bullish | Jan 11, 2021 | 5 years ago |
| SMA: Bullish | Jan 11, 2021 | 5 years ago |
| SMA: Bearish | Oct 19, 2020 | 6 years ago |
| SMA: Bearish | Oct 19, 2020 | 6 years ago |
| SMA: Bullish | Oct 5, 2020 | 6 years ago |
| SMA: Bullish | Oct 5, 2020 | 6 years ago |
| SMA: Bearish | Aug 31, 2020 | 6 years ago |
| SMA: Bearish | Aug 24, 2020 | 6 years ago |
| MACD: Sell Signal | Aug 24, 2020 | 6 years ago |
| RSI: Overbought | Jul 13, 2020 | 6 years ago |
| MACD: Buy Signal | Jul 6, 2020 | 6 years ago |
| SMA: Bullish | May 18, 2020 | 6 years ago |
| SMA: Bearish | Mar 30, 2020 | 6 years ago |
| SMA: Bullish | Feb 24, 2020 | 6 years ago |
| RSI: Overbought | Feb 24, 2020 | 6 years ago |
| SMA: Bearish | Feb 17, 2020 | 6 years ago |
| RSI: Overbought | Jan 27, 2020 | 6 years ago |
| SMA: Bullish | Jan 6, 2020 | 6 years ago |
| SMA: Bearish | Dec 16, 2019 | 6 years ago |
Key statistics
- Market cap
- 1.91B
- Enterprise value
- 1.55B
- Trailing P/E
- 0.00
- Forward P/E
- -4.54
- PEG ratio
- 0.00
- Price / sales
- 6.31
- Price / book
- 1.95
- EPS (TTM)
- -1.76
- Beta
- 1.59
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -83.00%
- Revenue (TTM)
- 303.23M
- Revenue growth
- 19582.50%
- Free cash flow
- -38.89M
- Total cash
- 532.73M
- Total debt
- 93.27M
- Return on equity
- -26.08%
- Shares outstanding
- 169.22M
- Short % of float
- 9.72%
- 50-day average
- 10.90
- 200-day average
- 9.50
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 21.00 +85.8% upside
Now 11.30
- Target (low)
- 15.00
- Target (mean)
- 21.00
- Target (high)
- 30.00
Ratings (0m) 10 10 buy · 0 hold · 0 sell
- Strong buy3
- Buy7
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate -0.73157.
Financials — quick view
VIR Revenue — quarterly 238.95M
VIR Net income — quarterly 80.08M
VIR EPS — quarterly 0.48
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | -0.73934 | — | — | — |
| Aug 5, 2026 | Jun 30, 2026 | 0.3326 | 0.47 | +0.14 | +41.31% |
| May 6, 2026 | Mar 31, 2026 | -0.01 | -0.85 | -0.84 | -8,400.00% |
| Feb 23, 2026 | Dec 31, 2025 | -0.42 | -0.31 | +0.11 | +26.19% |
| Nov 5, 2025 | Sep 30, 2025 | -0.70 | -1.17 | -0.47 | -67.14% |
| Aug 6, 2025 | Jun 30, 2025 | -0.72 | -0.80 | -0.08 | -11.11% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 7, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Jun 11, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Jun 3, 2026 | Leerink Partners | main | Outperform | Outperform |
| Mar 4, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Feb 25, 2026 | Barclays | main | Overweight | Overweight |
| Feb 24, 2026 | Morgan Stanley | main | Overweight | Overweight |
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- vir.bio
News
- Vir Biotechnology Announces Appointment of Suzanne Topalian to its Board of Directors
- Vir Biotechnology: A Big Pharma Collaboration And 2 Clinical Catalysts This Quarter
- Critical Survey: REGENXBIO (NASDAQ:RGNX) versus Vir Biotechnology (NASDAQ:VIR)
- Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth?
- Vir Biotechnology, Gilead Strike Deal for Novel Tumor Treatments
- Vir Biotechnology, Gilead Strike Deal for Novel Tumor Treatments
- Vir Biotechnology Signs Up To $1.875B Gilead Deal For 3 Cancer Drug Candidates; Gilead To Pay $65M Cash Upfront And Buy 1,765,486 Shares At $14.16 Each, For A Total Of $25M, Plus Up To $1.785B In Milestones And Royalties
- Vir Biotechnology Announces Collaboration, License Agreement With Gilead To Discover, Engineer Three PRO-XTEN Dual-Masked T-Cell Engager Development Candidates Targeting Selected Solid Tumor-Associated Antigens
- Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors
- Vir Biotechnology Receives FDA Fast Track Designation For VIR-5500 To Treat Metastatic Castration-Resistant Prostate Cancer
Your note
Sign in to keep a note on VIR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DE BACKER MARIANNE | Chief Executive Officer | Sale | Apr 5, 2026 | 1,001,260 |
| DE VERNEUIL VANINA ALEXANDRA HUARD | General Counsel | Sale | Feb 24, 2026 | 112,982 |
| EISNER MARK E | Officer | Sale | Feb 24, 2026 | 154,024 |
| HANLY ANN M | Chief Technology Officer | Sale | Feb 23, 2025 | 117,901 |
| MORE ROBERT J | Director | Stock Award(Grant) | May 26, 2026 | 558,573 |
| O'BYRNE JASON | Chief Financial Officer | Sale | Feb 23, 2026 | 162,615 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 12.22% | 20,678,283 | 233.66M | Jun 29, 2026 |
| Arch Venture Management, Llc | 7.50% | 12,694,163 | 143.44M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 6.79% | 11,495,215 | 129.90M | Jun 29, 2026 |
| SB Investment Advisers (UK) LTD | 6.47% | 10,948,093 | 123.71M | Jun 29, 2026 |
| State Street Corporation | 5.89% | 9,964,151 | 112.59M | Jun 29, 2026 |
| GSK plc | 5.05% | 8,550,954 | 96.63M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.86% | 4,846,948 | 54.77M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.09% | 3,533,092 | 39.92M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.05% | 3,476,669 | 39.29M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.50% | 2,546,144 | 28.77M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.18% | 1,996,625 | 22.56M | Jun 29, 2026 |
| VANGUARD HORIZON FUNDS-Vanguard Strategic Equity Fund | 1.04% | 1,762,412 | 19.92M | Jun 29, 2026 |